Puma Biotechnology, Inc. (PBYI) — Financial statements
Income statement, balance sheet, and cash flow for Puma Biotechnology, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 228↓0.9% | 230↓2.2% | 236↑3.3% | 228↓9.9% | 253 | |
| Cost of Revenue | 58↓9.7% | 64↑2.7% | 63↑13.8% | 55↓13.5% | 64 | |
| Gross Profit | 170↑2.5% | 166↓4.0% | 173↑0.0% | 173↓8.7% | 189 | |
| Operating Expenses | ||||||
| R&D Expenses | 62↑13.0% | 55↑9.0% | 50↓3.6% | 52↓27.3% | 72 | |
| General & Administrative Expenses | 71↓11.7% | 81↓8.8% | 88↓1.7% | 90↓22.6% | 116 | |
| Selling & Marketing Expenses | 0.00↑100.0% | -0.52↓158.9% | 0.88 | 0.00 | 0.00 | |
| SG&A Expenses | 71↓11.2% | 80↓10.2% | 89↓0.7% | 90↓22.6% | 116 | |
| Other Expenses | -0.36 | 0.00↓100.0% | 0.63↓91.1% | 7 | 0.00 | |
| Operating Expenses | 133↓1.6% | 135↓3.7% | 140↓6.0% | 149↓20.7% | 188 | |
| Total Costs & Expenses | 191↓4.2% | 200↓1.7% | 203↓0.6% | 204↓18.9% | 252 | |
| Operating Results | ||||||
| Operating Income | 37↑20.5% | 31↓5.1% | 33↑37.6% | 24↑1738.8% | 1 | |
| Depreciation & Amortization | 11↓5.1% | 12↑0.0% | 12↑17.1% | 10↓13.0% | 11 | |
| EBITDA | 53↑11.0% | 48↑1.2% | 48↑117.1% | 22↑566.7% | -5 | |
| EBIT | 42↑16.0% | 37↑1.5% | 36↑198.8% | 12↑175.3% | -16 | |
| Interest & Other Income | ||||||
| Net Interest Income | -3↑67.1% | -8↑27.9% | -11↑0.5% | -11↑14.8% | -13 | |
| Interest Income | 4↓13.7% | 5↑81.3% | 3↑220.4% | 0.81↑408.1% | 0.16 | |
| Interest Expense | 7↓46.8% | 12↓6.6% | 13↑15.0% | 12↓9.5% | 13 | |
| Non-Operating Income | -5↑8.6% | -6↓66.1% | -3↓128.8% | 12↓32.5% | 17 | |
| Other Income / Expenses | -2↑77.9% | -7↑31.1% | -10↑57.2% | -23↑22.7% | -30 | |
| Income Before Tax | 36↑48.5% | 24↑6.3% | 23↑4861.5% | 0.46↑101.6% | -29 | |
| Income Tax Expense | 5↑175.6% | -6↓670.5% | 1↑138.0% | 0.46↑40.4% | 0.32 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 31↑2.8% | 30↑40.2% | 22↑1079450.0% | 0.00↑100.0% | -29 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 31↑2.8% | 30↑40.2% | 22↑1079450.0% | 0.00↑100.0% | -29 | |
| Bottom-Line Net Income | 31↑2.8% | 30↑40.2% | 22↑1079450.0% | 0.00↑100.0% | -29 | |
| EPS (Basic) | 0.62↑0.0% | 0.62↑34.8% | 0.46↑2154.9% | 0.02↑102.8% | -0.72 | |
| EPS (Diluted) | 0.61↓1.6% | 0.62↑37.8% | 0.45↑2116.7% | 0.02↑102.8% | -0.72 | |
| Weighted Average Shares | 50↑2.8% | 49↑3.2% | 47↑5.5% | 45↑9.9% | 41 | |
| Weighted Average Diluted Shares | 51↑3.2% | 49↑3.3% | 48↑5.8% | 45↑10.6% | 41 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.